For the year ending 2025-12-31, SGMO made $39,552K in revenue. -$122,932K in net income. Net profit margin of -310.81%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Revenues | 39,552 | |||
| Research and development | 112,670 | |||
| General and administrative | 34,886 | |||
| Impairment of long-lived assets | 13,235 | |||
| Total operating expenses | 160,791 | |||
| Loss from operations | -121,239 | |||
| Interest income | 1,302 | |||
| Other (expense) income, net | -3,563 | |||
| Loss before income taxes | -123,500 | |||
| Income tax benefit | -568 | |||
| Net loss | -122,932 | |||
| Basic EPS | -0.44 | |||
| Diluted EPS | -0.44 | |||
| Basic Average Shares | 280,193,000 | |||
| Diluted Average Shares | 280,193,000 | |||
SANGAMO THERAPEUTICS, INC (SGMO)
SANGAMO THERAPEUTICS, INC (SGMO)